|1.||Dumas, J-P: 1 article (10/2007)|
|2.||Bonniaud, P: 1 article (10/2007)|
|3.||Camus, P: 1 article (10/2007)|
|4.||Guilloux, L: 1 article (10/2007)|
|5.||Favrolt, N: 1 article (10/2007)|
|6.||Collet, E: 1 article (10/2007)|
|7.||Pauli, G: 1 article (10/2007)|
|8.||Carie, A E: 1 article (05/2007)|
|9.||Sebti, S M: 1 article (05/2007)|
|10.||Mehra, Purvi K: 1 article (07/2005)|
01/01/1984 - "The combination of pirbuterol's beta 2 and lesser beta1 activity has proven helpful in the therapy of refractory congestive heart failure. "
09/01/1981 - "Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation."
03/01/1986 - "In conclusion, although acute rest hemodynamics improve with pirbuterol, the lack of improved acute exercise performance and the decrease in hemodynamic responsivity at six weeks appear to limit its usefulness in the treatment of heart failure."
01/01/1982 - "Because of the reported efficacy of oral doses, the direct relationship between plasma concentration and dosage, the positive inotropic properties, and the peripheral vasodilating effects of pirbuterol, investigation of the intravenous form of the drug in patients with severe decompensated low-output congestive heart failure seems warranted."
12/01/1983 - "Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial."
|2.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/1984 - "In the acute therapy of chronic obstructive pulmonary disease, pirbuterol is most effective in oral doses of 15-20 mg, and by aerosol in doses of 400 micrograms or greater. "
04/01/1983 - "In an open study in which 25 male outpatients with chronic obstructive pulmonary disease received pirbuterol aerosol for up to 14 months bronchodilator efficacy was maintained throughout. "
01/01/1989 - "Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD."
10/22/1983 - "Response of pulmonary circulation to oral pirbuterol in chronic airflow obstruction."
01/01/1989 - "Haemodynamic studies at rest and during exercise together with radionuclide ventriculography, pulmonary function and clinical well-being assessment were evaluated in ten patients with COPD and secondary pulmonary hypertension (mean PAP 25 mm Hg), before and after 6 months therapy with pirbuterol 20 mg thrice daily. "
07/01/1978 - "Side effects attributable to pirbuterol, nervousness and tremor, occurred in only 2 patients and were easily controlled."
01/01/1992 - "This study demonstrated that with the beta-2 specific agent pirbuterol, administered as a metered dose inhaler, there is little risk of development of skeletal muscle or cardiovascular toxicity when as much as three times the recommended dose is used in a single usage, and that there is no direct correlation between the onset, peak, and/or duration of tremor with the onset and peak of bronchodilator efficacy with this agent."
01/01/1992 - "In this investigation we evaluated the effect of increasing dosage, using an inhaled beta-2 specific agonist, pirbuterol, administered by a metered dose inhaler on pulmonary function, tremor, and cardiovascular parameters in nonacute adult asthmatic patients. "
06/01/1990 - "Reservations regarding the use of positive inotropic drugs for CHF have been supported by the results of studies showing that beta 1 agonists such as prenalterol and beta 2 agonists such as salbutamol or pirbuterol, due to down-regulation of beta-receptor density, are not capable of maintaining improved contractility during chronic treatment; intermittent dobutamine treatment resulted in higher mortality; beta-blockers without intrinsic sympathomimetic activity reduced mortality in patients with CHF after myocardial infarction while on use of beta-receptor blockers with intrinsic sympathomimetic activity, this favorable effect was not observed; during chronic PDH treatment, there was an unfavorable one-year mortality rate (50 to 100%); a controlled study with amrinone did not show a higher mortality than placebo. "
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
|10.||Adrenergic beta-Agonists (beta-Adrenergic Agonists)
|1.||Metered Dose Inhalers (Metered Dose Inhaler)
|2.||Nebulizers and Vaporizers (Inhaler)